Table 1 Summary of studies, rates and synthesis by cancer group and type.
From: Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours
Cancer type | NTRK fusion prevalence point estimate | 95% Confidence interval | Heterogeneity (I2) | Denominator |
|---|---|---|---|---|
Group—Brain/CNS | ||||
Glioma | 0.51 | 0.20–1.30% | I2 = 0.90 | 7889 |
Glioblastoma multiforme | 1.02 | 0.45–2.28% | I2 = 0.55 | 1095 |
Low grade glioma | 0.94 | 0.31–2.17% | – | 534 |
Astrocytoma | 2.22 | 0.90–4.51% | – | 316 |
Anaplastic astrocytoma | 0.00 | 0.00–2.74% | – | 133 |
Diffuse astrocytoma | 0.00 | 0.00–3.49% | – | 104 |
Oligodendroglioma | 0.00 | 0.00–4.12% | – | 88 |
Glioma NOS | 2.44 | 0.06–12.86% | – | 41 |
Glioma/neuroepithelial tumour | 0.55 | 0.24–1.07% | – | 1465 |
Diffuse leptomeningeal glioneuronal tumour | 10.00 | 2.11–26.53% | – | 30 |
Unknown neurological primary | 0.22 | 0.05–0.63% | – | 1386 |
Group—Breast Cancer | ||||
Breast cancer | 0.21 | 0.16–0.27% | I2 = 0.00 | 25,370 |
Breast cancer (excludes secretory breast) | 0.08 | 0.02–0.21% | – | 4854 |
Secretory carcinoma of the breast | 88.64 | 75.44–96.21% | – | 44 |
Group—CUP | ||||
Cancer of unknown primary (CUP) | 0.14 | 0.08–0.23% | – | 10,636 |
Group—Colorectal | ||||
Appendiceal adenocarcinoma | 0.48 | 0.01–2.65% | – | 208 |
Appendiceal cancer | 1.27 | 0.03–6.85% | – | 79 |
Colon adenocarcinoma | 0.23 | 0.13–0.37% | – | 7008 |
Colon cancer | 0.35 | 0.15–0.68% | – | 2306 |
Colorectal adenocarcinoma | 0.20 | 0.09–0.37% | – | 4569 |
Colorectal cancer | 0.22 | 0.18–0.28% | I2 = 0.02 | 29,578 |
MSI-high colorectal carcinoma | 3.25 | NA* | – | – |
MSI-stable colorectal carcinoma | 0.18 | NA* | – | – |
Deficient MMR colorectal cancer | 5.60 | 2.28–11.20% | – | 125 |
RAS/BRAF WT colorectal cancer | 0.50 | 0.01–2.77% | – | 199 |
RAS/BRAF WT, anti-EGFR resistant colorectal cancer | 4.26 | 0.52–14.5% | – | 47 |
Group—Genitourinary | ||||
Prostate cancer | 0.14 | 0.08–0.25% | I2 = 0.00 | 7845 |
Prostate adenocarcinoma | 0.00 | 0.00–0.73% | – | 502 |
Bladder cancer | 0.21 | 0.10–0.42% | I2 = 0.00 | 3831 |
Bladder urothelial carcinoma | 0.00 | 0.00–0.89% | – | 414 |
Renal clear cell carcinoma | 0.00 | 0.00–0.68% | – | 541 |
Metanephric adenoma | 10.00 | 1.23–31.70% | – | 20 |
Group—Gynaecological | ||||
Cervical cancer | 0.33 | 0.00–1.81% | – | |
Uterine | 0.19 | 0.02–0.67% | – | 1080 |
Uterine sarcoma | 1.15 | 0.14–4.09% | – | 174 |
Fallopian tube | 0.28 | 0.06–0.81% | – | 1078 |
Ovarian cancer | 0.18 | 0.11–0.28% | – | 11,590 |
Ovarian serous cystadenocarcinoma | 0.00 | 0.00–0.86% | – | 428 |
Group—Head and Neck | ||||
Head and neck (excluding salivary gland cancers) | 0.10 | 0.02–0.28% | – | 3145 |
Head and neck squamous cell carcinoma | 0.38 | 0.04–1.38% | – | 522 |
Salivary gland cancer (includes secretory carcinoma) | 2.50 | 1.60–3.69% | – | 962 |
Secretory carcinoma of the salivary gland | 83.33 | 69.78–92.52% | – | 48 |
Group—Lung | ||||
Lung | 0.06 | 0.03–0.10% | – | 21,115 |
Non-small cell lung cancer | 0.19 | 0.11–0.33% | I2 = 0.88 | 60,272 |
Non-squamous non-small lung cancer | 0.00 | 0.00–0.40% | – | 909 |
Lung adenocarcinoma | 0.09 | 0.03–0.31% | I2 = 0.32 | 8982 |
Lung squamous cell carcinoma | 0.00 | 0.00–0.73% | – | 502 |
Large cell neuroendocrine carcinoma | 1.45 | 0.04–7.81% | – | 69 |
Mucinous adenocarcinoma | 1.39 | 0.03–7.50% | – | 72 |
Small cell lung cancer | 1.64 | 0.20–5.80% | – | 122 |
EGFR, ALK, KRAS, ROS1 WT lung adenocarcinoma | 3.30 | 0.69–9.33% | – | 91 |
BRAF, KRAS, EGFR WT lung adenocarcinoma | 0.27 | 0.01–1.69% | – | 327 |
EGFR T790M 2nd Gen TKI resistant non-small cell lung cancer | 1.79 | 0.04–9.55% | – | 56 |
EGFRm post TKI non-small cell lung cancer | 0.10 | 0.03–0.26% | – | 3873 |
Group—Sarcoma | ||||
Sarcoma | 0.68 | 0.36–1.16% | – | 1915 |
Bone sarcoma | 0.16 | 0.00–0.90% | – | 616 |
Osteosarcoma | 2.65** | 0.55–7.56% | – | 113 |
Soft tissue sarcoma | 0.69 | 0.26–1.85% | I2 = 0.48 | 5080 |
Sarcoma NOS (excludes uterine) | 1.17 | 0.54–2.21% | – | 770 |
Gastrointestinal stromal tumours | 0.59 | 0.22–1.29% | – | 1009 |
Thoracic inflammatory myofibroblastic tumours | 9.09 | 1.92–24.33% | – | 33 |
Leiomyosarcoma | 0.27 | 0.09–0.62% | – | 1865 |
Group—Skin and Melanoma | ||||
Melanoma | 0.19 | 0.12–0.33% | I2 = 0.00 | 7203 |
Cutaneous melanoma | 0.76 | 0.16–2.20% | – | 395 |
Spitzoid neoplasms | 12.50 | 7.32–19.50% | – | 128 |
Spitzoid melanoma | 4.00 | 0.10–20.35% | – | 25 |
Mucosal/paramucosal melanoma | 0.89 | 0.02–4.83% | – | 113 |
Pigmented spindle cell nevus of reed | 56.52 | 34.49–76.81% | – | 23 |
Group—Thyroid | ||||
Thyroid cancer | 1.68 | 1.08–2.63% | I2 = 0.67 | 2679 |
Papillary thyroid cancer | 2.04 | 1.32–3.13% | I2 = 0.40 | 1552 |
Classic papillary thyroid cancer | 0.35 | 0.04–1.25% | – | 575 |
Classic papillary thyroid cancer (iodine refractory) | 5.08 | 1.06–14.15% | – | 59 |
Tall cell variant papillary thyroid cancer | 2.56 | 0.06–13.48% | – | 39 |
Anaplastic thyroid cancer | 1.02 | 0.12–3.64% | – | 196 |
Hurtle cell carcinoma | 2.86 | 0.07–14.92% | – | 35 |
Poorly differentiated thyroid cancer | 2.44 | 0.06–12.86% | – | 41 |
Malignant thyroid nodule | 0.48 | 0.01–2.64% | – | 209 |
Group—Upper Gastrointestinal | ||||
Gastric cancer | 0.14 | 0.05–0.33% | – | 3558 |
Small bowel cancer | 0.10 | 0.00–0.54% | – | 1027 |
Liver | 0.19 | 0.02–0.68% | – | 1064 |
Pancreatic cancer | 0.14 | 0.09–0.22% | I2 = 0.60 | 13,304 |
Pancreatic adenocarcinoma | 0.34 | 0.08–0.78% | – | 1492 |
Biliary tract cancer | 0.22 | 0.10–0.49% | I2 = 0.00 | 2735 |
Cholangiocarcinoma | 0.17 | 0.09–0.34% | I2 = 0.00 | 4692 |
Intrahepatic cholangiocarcinoma | 3.57 | 0.09–18.35% | – | 28 |
